Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
48,706,367
-
Share change
-
+8,346,734
-
Total reported value
-
$3,059,113,009
-
Put/Call ratio
-
99%
-
Price per share
-
$62.77
-
Number of holders
-
406
-
Value change
-
+$484,420,173
-
Number of buys
-
222
-
Number of sells
-
149
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2022
As of 31 Mar 2022,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
406 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,706,367 shares.
The largest 10 holders included
ARK Investment Management LLC, Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., Capital International Investors, BlackRock Inc., LOOMIS SAYLES & CO L P, FMR LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, and ARMISTICE CAPITAL, LLC.
This page lists
409
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.